drugset / Trial / NCT07098481
Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy
Phase 4
Not yet recruiting
576 enrolled
ANRS, Emerging Infectious Diseases
Centre de Recherche sur les Maladies Emergentes et Re-Emergentes (CREMER) · collabFaculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun · collabIRD, Epidemiologie et Prevention, Montpelier, France · collabPharmAccess · collabSESSTIM (IRD, Inserm, Université Aix-Marseille) · collabService d'hépato-gastroentérologie, Hôpital Saint Joseph, Marseille, France · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Hepatitis C is a common and potentially serious disease. However, there are treatments that can cure it. That's why it's so important to detect the hepatitis C virus (HCV) and treat those affected. Today, many hepatitis C sufferers in Cameroon (and elsewhere) remain untreated. The aim of this research is therefore to evaluate a simplified screening and treatment strategy (developed specifically for the Cameroonian context) in comparison with a standard strategy (based on usual care), in order to improve access to hepatitis C treatment in Cameroon. If the results of this research are positive, this strategy could be recommended to health authorities in Cameroon and other comparable countries.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vosevi | Unknown | 100 mg | Oral |
| Subject | Vosevi | Unknown | 400 mg | Oral |
| Subject | glecaprevir | Other / unclassified | 100 mg | Oral |
| Subject | glecaprevir | Other / unclassified | 400 mg | Oral |